Literature DB >> 19881537

c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.

H Scheller1, S Tobollik, A Kutzera, M Eder, J Unterlehberg, I Pfeil, B Jungnickel.   

Abstract

The germinal center (GC) reaction has a pivotal function in human B-cell lymphomagenesis. Genetic aberrations occurring during somatic hypermutation and class switch recombination deregulate key factors controlling B-cell physiology and proliferation. Several human lymphoma entities are characterized by a constitutive GC phenotype and ongoing somatic hypermutation, but the molecular basis for this phenomenon is only partly understood. We have investigated the reasons for a constitutive GC-like program in Burkitt's lymphoma cells. Here, overexpression of c-Myc leads to a centroblast phenotype, promotes high constitutive expression of the key GC factors Bcl-6, E2A and activation-induced cytidine deaminase and contributes to proliferation and somatic hypermutation. Our findings elucidate how the activity of a pivotal transcription factor may freeze B-cell lymphoma cells in a constitutive GC-like state that is even maintained at an extrafollicular location.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19881537     DOI: 10.1038/onc.2009.377

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  hIgD promotes human Burkitt lymphoma Daudi cell proliferation by accelerated G1/S transition via IgD receptor activity.

Authors:  Xing Dai; YuJing Wu; XiaoYi Jia; Yan Chang; HuaXun Wu; Chun Wang; HengShi Chen; WenSheng Chen; Qiong Huang; Wei Wei
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

2.  CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection.

Authors:  Rodolfo Silva; Susan Moir; Lela Kardava; Karen Debell; Venkateswara R Simhadri; Sara Ferrando-Martínez; Manuel Leal; José Peña; John E Coligan; Francisco Borrego
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

3.  Regulation of memory B-cell survival by the BH3-only protein Puma.

Authors:  Cyril Clybouw; Silke Fischer; Marie Thérèse Auffredou; Patricia Hugues; Catherine Alexia; Philippe Bouillet; Martine Raphael; Gérald Leca; Andreas Strasser; David M Tarlinton; Aimé Vazquez
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

4.  HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma.

Authors:  Lei Li; Yin-Li Zheng; Chen Jiang; Shuo Fang; Ting-Ting Zeng; Ying-Hui Zhu; Yan Li; Dan Xie; Xin-Yuan Guan
Journal:  Cell Death Differ       Date:  2019-02-18       Impact factor: 15.828

5.  Myc roles in hematopoiesis and leukemia.

Authors:  M Dolores Delgado; Javier León
Journal:  Genes Cancer       Date:  2010-06

6.  Checkpoint kinase 2 is required for efficient immunoglobulin diversification.

Authors:  Kathrin Davari; Samantha Frankenberger; Angelika Schmidt; Nils-Sebastian Tomi; Berit Jungnickel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Critical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma.

Authors:  Xin Jiang; Honggang Guo; Jianguo Wu; Qiang He; Yiqiao Li; Miao Wang; Hongyang Pan; Wande Li; Jinjie Wang; Qingqing Wang; Jing Shen; Yuehai Ke; Ren Zhou
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

8.  Checkpoint kinase 1 negatively regulates somatic hypermutation.

Authors:  Samantha Frankenberger; Kathrin Davari; Sabine Fischer-Burkart; Katrin Böttcher; Nils-Sebastian Tomi; Ursula Zimber-Strobl; Berit Jungnickel
Journal:  Nucleic Acids Res       Date:  2014-01-13       Impact factor: 16.971

Review 9.  Epstein-Barr virus-associated lymphomas.

Authors:  Claire Shannon-Lowe; Alan B Rickinson; Andrew I Bell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

10.  Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy.

Authors:  Jingcheng Zhang; Yifen Shi; Mingzhe Zhao; Huixian Hu; He Huang
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.